Greenhaven Road Capital: Short Term Gain Realized from Liquidia (LQDA), Investment to Be Revisited

Greenhaven Road Capital's Q2 2026 investor letter unveiled a 11% net return, building on gains made in the first quarter. The firm plans to reduce its portfolio concentration and increase investments with near-term opportunities, while taking a proactive approach to profit-taking. Emphasis remains on investing in strong businesses and challenging consensus views, as several major holdings are set for significant events in the coming year.

Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing therapies for rare cardiopulmonary diseases, was singled out in the letter. On August 14, 2026, the stock closed at $74.44 per share, with a one-month return of 0.26% and a 52-week gain of 178.79%. Liquidia Corporation (NASDAQ:LQDA) has a market capitalization of $6.66 billion.

The fund's Q2 2026 investor letter highlighted Liquidia Corporation (NASDAQ:LQDA) as a "special situation," noting the company's successful drug launch and the pending patent dispute. Greenhaven Road Capital had purchased shares below their estimated settlement price, even after an adverse trial outcome. The shares had appreciated more than 30% before a verdict, resulting in a short-term gain. The fund will reassess the investment following the resolution.

Liquidia Corporation (NASDAQ:LQDA) does not appear in the list of the 40 most popular stocks among hedge funds. According to the fund's records, 41 hedge fund portfolios held the company at the end of the first quarter, compared to 44 in the previous quarter. Despite recognizing the potential of Liquidia Corporation (NASDAQ:LQDA), the firm believes that other AI stocks present greater upside potential with lower downside risk.

The fund suggested exploring a free report on the best short-term AI stock for those seeking an extremely undervalued investment in this sector.